» Articles » PMID: 21566655

Expression of CD34 and CD7 on Human T-cell Acute Lymphoblastic Leukemia Discriminates Functionally Heterogeneous Cell Populations

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2011 May 14
PMID 21566655
Citations 37
Authors
Affiliations
Soon will be listed here.
Abstract

Leukemia-initiating/repopulating cells (LICs), also named leukemic stem cells, are responsible for propagating human acute leukemia. Although they have been characterized in various leukemias, their role in T-cell acute lymphoblastic leukemia (T-ALL) is unclear. To identify and characterize LICs in T-ALL (T-LIC), we fractionated peripheral blood cell populations from patient samples by flow cytometry into three cell fractions by using two markers: CD34 (a marker of immature cells and LICs) and CD7 (a marker of early T-cell differentiation). We tested these populations in both in vitro culture assays and in vivo for growth and leukemia development in immune-deficient mice. We found LIC activity in CD7(+) cells only as CD34(+)CD7(-) cells contained normal human progenitors and hematopoietic stem cells that differentiated into T, B lymphoid and myeloid cells. In contrast, CD34(+)CD7(+) cells were enriched in LICs, when compared with CD34(-)CD7(+) cells. These CD34(+)CD7(+) cells also proliferated more upon NOTCH activation than CD34(-)CD7(+) cells and were sensitive to dexamethasone and NOTCH inhibitors. These data show that CD34 and CD7 expression in human T-ALL samples help in discriminating heterogeneous cell populations endowed with different LIC activity, proliferation capacity and responses to drugs.

Citing Articles

The mitochondria as an emerging target of self-renewal in T-cell acute lymphoblastic leukemia.

Al-Hamaly M, Winter E, Blackburn J Cancer Biol Ther. 2025; 26(1):2460252.

PMID: 39905687 PMC: 11801350. DOI: 10.1080/15384047.2025.2460252.


Targeting LMO2-induced autocrine FLT3 signaling to overcome chemoresistance in early T-cell precursor acute lymphoblastic leukemia.

Tremblay C, Saw J, Yan F, Boyle J, Amarasinghe O, Abdollahi S Leukemia. 2025; 39(3):577-589.

PMID: 39849166 PMC: 11879882. DOI: 10.1038/s41375-024-02491-5.


The role of quiescent thymic progenitors in TAL/LMO2-induced T-ALL chemotolerance.

OConnor K, Kishimoto K, Kuzma I, Wagner K, Selway J, Roderick J Leukemia. 2024; 38(5):951-962.

PMID: 38553571 PMC: 11073972. DOI: 10.1038/s41375-024-02232-8.


The ESCRT protein CHMP5 promotes T cell leukemia by controlling BRD4-p300-dependent transcription.

Umphred-Wilson K, Ratnayake S, Tang Q, Wang R, Devaiah B, Zhou L bioRxiv. 2024; .

PMID: 38352301 PMC: 10862731. DOI: 10.1101/2024.01.29.577409.


Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?.

Zhang Z, Yang K, Zhang H Cancers (Basel). 2022; 14(22).

PMID: 36428753 PMC: 9688677. DOI: 10.3390/cancers14225655.